

## Supporting Information

### Oxidative Organocatalysed Enantioselective Coupling of Indoles with Aldehydes that Forms Quaternary Carbon Stereocentres

Nomaan M. Rezayee, Vibeke H. Lauridsen, Line Næsborg, Thanh V. Q. Nguyen, Henriette N. Tobiesen and Karl Anker Jørgensen\*

Department of Chemistry, Aarhus University  
DK-8000 Aarhus C, Denmark  
e-mail: kaj@chem.au.dk

#### Table of Contents

1.	General Methods	S2
2.	Synthesis of Starting Materials	S3
2.1	Synthesis of Aldehydes	S3
2.2	Synthesis of Catalysts	S4
3.	Optimisation Studies	S5
4.	General Procedures for the Enantioselective Coupling of Indoles to Aldehydes	S6
4.1	Asymmetric Synthesis of Oxidative Cross-coupling Products <b>4a-v</b> Using DDQ as Oxidant	S6
4.2	Asymmetric Synthesis of Oxidative Cross-coupling Products <b>4a,g,r,u</b> Using O <sub>2</sub> as Terminal Oxidant	S7
4.3	Characterization of Chiral Oxidative Cross-coupling Products <b>4a-v</b>	S8
5.	Homo-coupling of <b>1a</b> using <b>3d</b> or <b>3g</b>	S16
6.	Radical Clock and Trapping Experiments	S17
6.1	Allylamine Trapping Experiment	S17
6.2	Cyclopropyl Radical Clock Experiment	S17
6.3	BHT Trapping Experiment	S18
7.	Crystallographic Data	S19
8.	Computational Studies	S20
8.1	Ground state Computations	S21
9.	NMR Spectra	S27
10.	UPC <sup>2</sup> -traces	S54

## 1. General Methods

NMR spectra were acquired on a Bruker AVANCE III HD spectrometer running at 400 MHz for  $^1\text{H}$ , 100 MHz for  $^{13}\text{C}$  and 376 MHz for  $^{19}\text{F}$ . Chemical shifts ( $\delta$ ) are reported in ppm relative to residual solvent signals ( $\text{CHCl}_3$ , 7.26 ppm for  $^1\text{H}$  NMR;  $\text{CDCl}_3$ , 77.16 ppm for  $^{13}\text{C}$  NMR). Chemical shifts ( $\delta$ ) for  $^{19}\text{F}$  NMR are reported in ppm relative to  $\text{CFCl}_3$  as external reference. The following abbreviations are used to indicate the multiplicity in NMR spectra: s, singlet; d, doublet; t, triplet; q, quartet; p, pentet; dd, double doublet; ddd, double double doublet; dt, double triplet; td, triple doublet; tt, triple triplet; m, multiplet; bs, broad signal.  $^{13}\text{C}$  NMR spectra were acquired in a broad band decoupled mode. Mass spectra were recorded on a Bruker MicroTOF-Q High-Performance LC-MS system using electrospray ( $\text{ES}^+$ ) ionisation. Dichloromethane was dried over molecular sieves (4 Å). Analytical thin layer chromatography (TLC) was performed using pre-coated aluminium-backed plates (Merck Kieselgel 60 F<sub>254</sub>) and visualised by UV radiation, *p*-anisaldehyde stain or 2,4-DNPH stain. For flash chromatography (FC) Iatrobeads were used. Optical rotations were measured on a Bellingham + Stanley ADP440+ polarimeter,  $[\alpha]$  values are given in  $\text{deg}\cdot\text{cm}^3\cdot\text{g}^{-1}\cdot\text{dm}^{-1}$ ; concentration c in  $\text{g}\cdot(100 \text{ mL})^{-1}$ . The enantiomeric excess (ee) of the products was determined by chiral stationary phase Waters ACQUITY UPC<sup>2</sup> (Daicel Chiralpak). H<sub>2</sub>-DDQ was synthesised according to literature procedure.<sup>1</sup> Racemic samples for UPC<sup>2</sup> analysis were prepared using achiral 1-(2-aminoethyl)piperidine **3h** as catalyst.


---

1. C. Qiu, L. Jin, Z. Huang, Z. Tang, A. Lei, Z. Shen, N. Sun, W. Mo, B. Hu, X. Hu, *ChemCatChem* 2012, **4**, 76-80.


## 2. Synthesis of Starting Materials

### 2.1 Synthesis of Aldehydes

Aldehydes **1a,m-o,s,u** were prepared according to a known literature procedure.<sup>2</sup> Aldehyde **1r** is commercially available and was purified by FC before use. Aldehydes **1q,r,t** were prepared according to known literature procedures.<sup>3</sup> All aldehydes were stored at -20 °C under an Ar atmosphere.



To a stirring solution of  $\text{NaH}$  (60% in mineral oil, 1.05 g, 26.2 mmol) in dry DMSO (30 mL),  $\text{Me}_3\text{S}(\text{O})\text{I}$  (5.76 g, 26.2 mmol) was added at RT. The reaction mixture was left stirring for 1 h at RT. 3-Bromo-4-methoxyacetophenone (5.00 g, 21.8 mmol) was added portion-wise and the reaction mixture was left stirring overnight. The reaction mixture was diluted with  $\text{H}_2\text{O}$  (40 mL), followed by extractions with EtOAc (3 x 40 mL). The combined organic phases were dried over  $\text{Na}_2\text{SO}_4$  and the solvent was evaporated under vacuum to yield the crude epoxide. The epoxide was used without further purification.



Toluene (28 mL) was added to a round bottom flask equipped with the epoxide,  $\text{ZnCl}_2$  (1.49 g, 10.9 mmol), and stir bar. The resulting solution was heated and held at reflux for 3 h. Subsequent solvent removal and purification via FC on silica gel ( $\text{CH}_2\text{Cl}_2$ :pentane 75%) yielded the desired product (1.2 g, 23%).

**4q**  $^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  9.64 (d,  $J$  = 1.5 Hz, 1H), 7.40 (d,  $J$  = 2.3 Hz, 1H), 7.11 (dd,  $J$  = 8.4, 2.3 Hz, 1H), 6.90 (d,  $J$  = 8.4 Hz, 1H), 3.90 (s, 3H), 3.56 (q,  $J$  = 7.0 Hz, 1H), 1.42 (d,  $J$  = 7.0 Hz, 3H).

$^1\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):  $\delta$  200.7, 155.5, 133.2, 131.2, 128.5, 112.5, 112.4, 56.5, 51.9, 14.8.

**HRMS** (ESI+)  $m/z$  calcd. for  $\text{C}_{10}\text{H}_{12}\text{BrO}_2$  [ $\text{M}+\text{H}]^+$ : 243.0015; found: 243.0014.

2. X. Mo, D. G. Hall, *J. Am. Chem. Soc.* 2016, **138**, 10762-10765.

3. D. Destro, S. Sanchez, M. Cortigiani, M. F. A. Adamo, *Org. Biomol. Chem.* 2017, **15**, 5227-5235.

## 2.2 Synthesis of Catalysts

Synthesis of aminocatalysts **3d,e** were performed using literature procedures<sup>4,5</sup> and analytical data were found to be in accordance with the previously reported values.<sup>6</sup>


Synthesis of aminocatalyst **3f** is not reported in the literature references and characterisation data have been provided.

Boc-L-*tert*-leucine (1.00 g, 4.32 mmol, 1.00 equiv.) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (7.0 mL) and cooled to 0 °C. A solution of DCC (936 mg, 4.54 mmol, 1.05 equiv.) in dry CH<sub>2</sub>Cl<sub>2</sub> (5.0 mL) was slowly added. The mixture was stirred for 30 min. before (2*R*,5*R*)-2,5-diphenylpyrrolidine (965 mg, 4.32 mmol, 1.00 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (2.0 mL) was added dropwise. The resulting mixture was stirred overnight (27 h) before the precipitate was filtered off and washed with CH<sub>2</sub>Cl<sub>2</sub>. The filtrate was washed with 2% HCl (aq.), 4% NaHCO<sub>3</sub> (aq.) and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The residue was purified by FC on silica gel (pentane/EtOAc) to give the desired product with impurities in ca. 65% yield. No further purification was done and the unclean product was used directly for the next step.

The product (1.24 g, 2.84 mmol, 1.00 equiv.) was dissolved in MeOH (8.0 mL) and cooled to 0 °C. Acetyl chloride (1.80 mL, 25.2 mmol, 8.90 equiv.) was slowly added. The mixture was stirred at RT overnight (18 h). After 18 h full conversion of the starting material was observed by TLC analysis and the solvent was removed under reduced pressure. CH<sub>2</sub>Cl<sub>2</sub> (4 mL) and H<sub>2</sub>O (4 mL) were added to dissolve the compound and the pH value was adjusted to ca. 12 by addition of solid K<sub>2</sub>CO<sub>3</sub>. The aqueous phase was extracted with CH<sub>2</sub>Cl<sub>2</sub> (4 x) and the combined organic phase dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated. The residue was used directly in the next step without any purification.

The amide (1.1 g, 3.3 mmol, 1.0 equiv.) was dissolved in THF (anhyd., 10 mL) and cooled to 0 °C. LiAlH<sub>4</sub> (0.5 g, 13 mmol, 4.0 equiv.) was added in small portions under stirring. The reaction was stirred 30 min. at 0 °C before the ice bath was removed and stirring continued at RT overnight. After 22 h the reaction was carefully quenched by addition of NaOH (aq., 4 M) while cooled in an ice bath. The solids were filtered off and washed by THF. The filtrate was dried with Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure to leave a pale yellow oil. The product was purified by FC on silica gel (column packed with CH<sub>2</sub>Cl<sub>2</sub>, sample loaded, 15 mL CH<sub>2</sub>Cl<sub>2</sub> with 1% Et<sub>3</sub>N, then CH<sub>2</sub>Cl<sub>2</sub> to CH<sub>2</sub>Cl<sub>2</sub> with 8% MeOH).

The desired product was collected as a yellow oil in 47% yield (36% yield over the three steps).



**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 7.38 – 7.30 (m, 8H), 7.25 (tt, *J* = 5.8, 1.9 Hz, 2H), 4.38 – 4.29 (m, 2H), 2.65 (dd, *J* = 12.0, 2.5 Hz, 1H), 2.62 – 2.49 (m, 2H), 2.35 (dd, *J* = 12.0, 2.5 Hz, 1H), 2.03 – 1.91 (m, 3H), 0.58 (s, 9H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 143.6 (2C), 128.6 (4C), 128.1 (4C), 127.3 (2C), 66.0 (2C), 56.7, 47.8, 33.7 (2C), 32.8, 26.1 (3C).

**HRMS (ESI+)** *m/z* calcd. for C<sub>22</sub>H<sub>31</sub>N<sub>2</sub> [M+H]<sup>+</sup>: 323.2497; found: 323.2482.

4. L. M. Schneider, V. M. Schmiedel, T. Pecchioli, D. Lentz, C. Merten, M. Christmann, *Org. Lett.* 2017, **19**, 2310–2313.

5. S. Duan, S. Li, X. Ye, N.-N. Du, C.-H. Tan, Z. Jiang, *J. Org. Chem.* 2015, **80**, 7770–7778.

6. Y. Gao, Q. Ren, L. Wang, J. Wang, *Chem. Eur. J.* 2010, **16**, 13068–13071.

### 3. Optimisation Studies

**Table S1.** Screening of catalysts and oxidants for the enantioselective coupling of aldehyde **1a** to indole **2a**.<sup>a</sup>

Chemical structures of catalysts **3a-i**:


- 3a:** A bicyclic imine derivative with a TFA group.
- 3b:** A diamine derivative where R=H.
- 3c:** A diamine derivative where R=Me.
- 3d:** A diamine derivative where X=O.
- 3e:** A diamine derivative where X=C.
- 3f:** A bicyclic imine derivative with a Ph group.
- 3g:** A bicyclic imine derivative with a quinoline ring.
- 3h:** A diamine derivative.
- 3i:** A diamine derivative with a quinoline ring.

Entry	Cat.	Acid [R]	Oxidant	Temp. [°C]	Time [h]	Yield [%]	ee [%]
1 <sup>b</sup>	<b>3a</b>	-	CAN	RT	3	0	-
2 <sup>b</sup>	<b>3a</b>	-	CAN	-20	16	0	-
3 <sup>c</sup>	<b>3b</b>	-	CAN	-20	16	0	-
4 <sup>c</sup>	<b>3b</b>	-CN	CAN	-20	16	0	-
5 <sup>b</sup>	<b>3a</b>	-	Cu(OTf) <sub>2</sub>	-20	16	0	-
6 <sup>c</sup>	<b>3b</b>	-	Cu(OTf) <sub>2</sub>	-20	16	0	-
7	<b>3b</b>	-	DDQ	RT	16	38	-
8	<b>3c</b>	-	DDQ	RT	16	0	-
9	<b>3d</b>	-	DDQ	RT	16	41	66
10	<b>3d</b>	-OMe	DDQ	RT	3	50 <sup>d</sup>	62
11	<b>3d</b>	-H	DDQ	RT	3	70 <sup>d</sup>	66
12	<b>3d</b>	-CN	DDQ	RT	3	70	70
13	<b>3d</b>	-CN	Fluoranil	RT	3	31	63
14	<b>3d</b>	-CN	Chloranil	RT	3	10	43
15	<b>3e</b>	-CN	DDQ	RT	3	63	58
16	<b>3f</b>	-CN	DDQ	RT	3	64	82
17 <sup>e</sup>	<b>3f</b>	-CN	DDQ	RT	3	73	94
18	<b>3g</b>	-CN	DDQ	RT	3	0	-
19	<b>3h</b>	-CN	DDQ	RT	3	45	-
20	<b>3i</b>	-CN	DDQ	RT	3	30	37

<sup>a</sup> Performed on a 0.10 mmol scale under Ar: 1.0 equiv. **1**, 5.0 equiv. **2**, 0.20 equiv. **3**, 1.5 equiv. acid, 1.1 equiv. oxidant and 0.4 mL CH<sub>2</sub>Cl<sub>2</sub>. <sup>b</sup> 2.0 equiv. oxidant and 0.4 mL DME. <sup>c</sup> 2.0 equiv. oxidant and 0.4 mL CH<sub>2</sub>Cl<sub>2</sub>. <sup>d</sup> Determined by NMR (1,3,5-trimethoxybenzene was used as standard). <sup>e</sup> DDQ added in portions.

## 4. General Procedures for the Enantioselective Coupling of Indoles to Aldehydes


### 4.1 Asymmetric Synthesis of Oxidative Cross-coupling Products 4a-v Using DDQ as Oxidant



#### General Procedure A:

To a flame-dried 4 mL glass vial equipped with a magnetic stirring bar, reagents and solvent were added in the following order; catalyst **3f** (0.020 mmol, 20 mol%), *p*-CN-benzoic acid (0.15 mmol, 1.5 equiv.), indole **2** (0.5 mmol, 5 equiv.), aldehyde **1** (0.1 mmol, 1 equiv.) and anhyd. CH<sub>2</sub>Cl<sub>2</sub> (0.4 mL). The vial was quickly flushed with Ar and the first portion of DDQ (0.05 mmol, 0.5 equiv.) was added. After 15 min. of stirring, the last portion of DDQ (0.06 mmol, 0.6 equiv.) was added and the reaction was stirred for the noted amount of time at RT to afford the chiral oxidative cross-coupling products **4**.

## 4.2 Asymmetric Synthesis of Oxidative Cross-coupling Products **4a,g,r,u** Using O<sub>2</sub> as Terminal Oxidant




### General Procedure B:

To a flame-dried 4 mL glass vial equipped with a magnetic stirring bar and a cap containing a PTFE/silicone septum, H<sub>2</sub>-DDQ was added. In another flame-dried vial *t*BuONO was predissolved in 0.4 mL anhyd. CH<sub>2</sub>Cl<sub>2</sub> and transferred to the vial containing the H<sub>2</sub>-DDQ. An oxygen balloon was added and the suspension stirred at RT for 1.5 h. Following this, the solvent was removed *via* evaporation using a N<sub>2</sub> stream and added portions-wise to a third flame-dried 4 mL vial containing the catalyst **3f** (0.02 mmol, 20 mol%), *p*-CN-benzoic acid (0.15 mmol, 1.5 equiv.), indole **2** (0.5 mmol, 5 equiv.), aldehyde **1** (0.1 mmol, 1 equiv.) and 0.4 mL CH<sub>2</sub>Cl<sub>2</sub>. The vial was flushed with Ar and the reaction was stirred at RT for 3 h to afford the chiral oxidative cross-coupling products **4**.

### 4.3 Characterisation of Chiral Oxidative Cross-coupling Products 4a-v

#### (R)-2-(1H-Indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4a



Following the general procedure A, the product was isolated in 82% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent. Following the general procedure B, the product was isolated in 73% yield. Following the general procedure C, the product was isolated in 53% yield.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  10.03 (s, 1H), 8.31 (bs, 1H), 7.73 – 7.60 (m, 3H), 7.43 – 7.37 (m, 1H), 7.30 (dd,  $J = 8.6, 2.0$  Hz, 1H), 7.22 – 7.08 (m, 4H), 7.05 – 6.99 (m, 1H), 6.95 – 6.84 (m, 1H), 3.92 (s, 3H), 1.92 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.2, 158.0, 137.1, 136.5, 133.7, 129.7, 129.0, 127.5, 126.6, 126.3, 125.9, 123.5, 122.4, 121.2, 119.8, 119.1, 115.8, 111.6, 105.6, 55.7, 55.5, 23.1.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{22}\text{H}_{19}\text{NO}_2$  [ $\text{M}+\text{H}]^+$ : 330.1489; found: 330.1492.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 4.25$  min;  $t_{\text{minor}} = 4.53$  min; **General Procedure A:** 94% ee.  $[\alpha]_D^{25} = +21.3$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ). **General Procedure B:** 90% ee.

#### (R)-2-(5-Methoxy-1H-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4b



Following the general procedure A, the product was isolated in 67% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent. Following the general procedure B, the product was isolated in 73% yield.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.98 (s, 1H), 8.18 (bs, 1H), 7.74 – 7.58 (m, 3H), 7.36 – 7.20 (m, 2H), 7.20 – 7.06 (m, 3H), 6.83 (dd,  $J = 8.8, 2.5$  Hz, 1H), 6.44 (d,  $J = 2.5$  Hz, 1H), 3.92 (s, 3H), 3.49 (s, 3H), 1.91 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.1, 158.0, 153.9, 136.3, 133.7, 132.2, 129.7, 129.0, 127.4, 126.7, 126.4, 126.4, 124.3, 119.1, 115.5, 112.6, 112.2, 105.6, 103.1, 55.8, 55.7, 55.5, 23.0.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{23}\text{H}_{21}\text{NO}_3$  [ $\text{M}+\text{Na}]^+$ : 382.1414; found: 382.1421. **UPC<sup>2</sup>:**

Chiralpak IB-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 4.47$  min;  $t_{\text{minor}} = 4.71$  min; **General Procedure A:** 93% ee.  $[\alpha]_D^{27} = +6.5$  ( $c$  0.5,  $\text{CH}_2\text{Cl}_2$ ).

#### (R)-3-(2-(6-Methoxynaphthalen-2-yl)-1-oxopropan-2-yl)-1H-indole-5-carbonitrile, 4c



Following the general procedure A, the product was isolated in 33% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2:\text{EtOAc}$  100:0 to 98:2 as eluent. Following the general procedure B, the product was isolated in 65% yield.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.95 (s, 1H), 8.61 (bs, 1H), 7.71 (d,  $J = 8.6, 1$  H), 7.67 (d,  $J = 8.9$  Hz, 1H), 7.63 – 7.60 (m, 1H), 7.48 – 7.43 (m, 1H), 7.41 – 7.35 (m, 2H), 7.34 – 7.31 (m, 1H), 7.23 (dd,  $J = 8.6, 2.0$  Hz, 1H), 7.19 – 7.13 (m, 2H), 3.93 (s, 3H), 1.93 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.5, 158.3, 138.7, 135.3, 134.0, 129.7, 129.0, 127.9, 126.7, 126.3, 126.1, 125.8, 125.5, 125.5, 120.5, 119.5, 117.6, 112.6, 105.8, 103.2, 55.5, 55.4 23.0.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{23}\text{H}_{18}\text{N}_2\text{O}_2$  [ $\text{M}+\text{H}]^+$ : 355.1441; found: 355.1443.

**UPC<sup>2</sup>:** Chiralpak ID-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 3.94$  min;  $t_{\text{minor}} = 4.04$  min; **General Procedure A:** 88% ee.  $[\alpha]_D^{25} = -1.24$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(6-Methoxynaphthalen-2-yl)-2-(7-methyl-1H-indol-3-yl)propanal, 4d**



**4d**

Following the general procedure A, the product was isolated in 55% yield as a brown oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  10.04 (s, 1H), 8.21 (bs, 1H), 7.76 – 7.60 (m, 3H), 7.30 (dd,  $J$  = 8.6, 2.0 Hz, 1H), 7.21 (d,  $J$  = 2.6 Hz, 1H), 7.19 – 7.10 (m, 2H), 6.98 (d,  $J$  = 6.9 Hz, 1H), 6.91 – 6.79 (m, 2H), 3.92 (s, 3H), 2.52 (s, 3H), 1.92 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.2, 158.0, 136.7, 136.6, 133.7, 129.7, 129.0, 127.5, 126.6, 126.3, 125.5, 123.1, 123.0, 120.7, 120.1, 119.1, 119.0, 116.5, 105.6, 55.8, 55.5, 23.1, 16.8.

**HRMS** (ESI+)  $m/z$  calcd. for  $\text{C}_{23}\text{H}_{21}\text{NO}_2$  [ $\text{M}+\text{H}]^+$ : 344.1645; found: 344.1644.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $i\text{PrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 4.33$  min;  $t_{\text{minor}} = 4.81$  min; **General Procedure A:** 85% ee.  $[\alpha]_D^{24} = +27.4$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(5-Fluoro-1H-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4e**



**4e**

Following the general procedure A, the product was isolated in 66% yield as a yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.

**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.95 (s, 1H), 8.26 (bs, 1H), 7.84 – 7.54 (m, 3H), 7.33 – 7.24 (m, 2H), 7.21 (d,  $J$  = 2.6 Hz, 1H), 7.16 – 7.09 (m, 2H), 6.89 (td,  $J$  = 9.0, 2.6 Hz, 1H), 6.64 (dd,  $J$  = 9.9, 2.6 Hz, 1H), 3.90 (s, 3H), 1.88 (s, 3H).


**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.8, 158.1, 157.6 (d,  $J$  = 234 Hz), 135.9, 133.8, 133.5, 129.7, 129.0, 127.6, 126.4, 126.3, 126.3, 125.1, 119.2, 116.2 (d,  $J$  = 5 Hz), 112.2 (d,  $J$  = 9 Hz), 111.1 (d,  $J$  = 24 Hz), 106.1 (d,  $J$  = 24 Hz), 105.7, 55.5, 55.5, 22.9.

**$^{19}\text{F NMR}$  (376 MHz,  $\text{CDCl}_3$ ):**  $\delta$  -123.4 (s, 1F).

**HRMS** (ESI+)  $m/z$  calcd. for  $\text{C}_{22}\text{H}_{18}\text{FNO}_2$  [ $\text{M}+\text{H}]^+$ : 348.1394; found: 348.1398.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $i\text{PrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 8.83$  min;  $t_{\text{minor}} = 8.65$  min; **General Procedure A:** 86% ee.  $[\alpha]_D^{27} = +16.6$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(5-Chloro-1H-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4f**



**4f**

Following the general procedure A, the product was isolated in 64% yield as a brown oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.98 (s, 1H), 8.34 (bs, 1H), 7.76 – 7.60 (m, 3H), 7.36 – 7.26 (m, 2H), 7.23 – 7.09 (m, 4H), 7.03 (d,  $J$  = 2.0 Hz, 1H), 3.92 (s, 3H), 1.91 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.9, 158.1, 135.9, 135.4, 133.8, 129.7, 129.0, 127.6, 127.0, 126.4 (s, 2C), 125.6, 124.8, 123.0, 120.4, 119.3, 116.0, 112.6, 105.7, 55.6, 55.5, 23.0.

**HRMS** (ESI+)  $m/z$  calcd. for  $\text{C}_{22}\text{H}_{18}\text{ClNO}_2$  [ $\text{M}+\text{H}]^+$ : 364.1099; found: 364.1100.

**UPC<sup>2</sup>:** Chiralpak IB-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $i\text{PrOH}$  (0.5 min), then gradient from 1% to 40% (1.24%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 19.05$  min;  $t_{\text{minor}} = 19.39$  min; **General Procedure A:** 85% ee.  $[\alpha]_D^{25} = +8.2$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(5-Bromo-1H-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4g**



Following the general procedure A, the product was isolated in 88% yield as a yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent. Following the general procedure C, the product was isolated in 82% yield.

**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.98 (s, 1H), 8.32 (bs, 1H), 7.75 – 7.61 (m, 3H), 7.32 – 7.26 (m, 3H), 7.22 – 7.11 (m, 4H), 3.93 (s, 3H), 1.91 (s, 3H).


**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.9, 158.1, 135.8, 135.7, 133.9, 129.7, 129.0, 127.6 (2C), 126.4, 126.4, 125.6, 124.7, 123.5, 119.3, 116.0, 113.2, 113.1, 105.7, 55.6, 55.5, 23.0.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{22}\text{H}_{18}\text{BrNO}_2$  [ $\text{M}+\text{H}]^+$ : 408.0594; found: 408.0591.

**UPC<sup>2</sup>:** Chiralpak IB-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 4.90$  min;  $t_{\text{minor}} = 4.99$  min;

**General Procedure A:** 90% ee.  $[\alpha]_D^{25} = -9.6$  (*c* 0.5,  $\text{CH}_2\text{Cl}_2$ ). **General Procedure B:** 80% ee.

**(R)-2-(6-Fluoro-1*H*-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4h**



Following the general procedure A, the product was isolated in 55% yield as a yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.

**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.98 (s, 1H), 8.23 (bs, 1H), 7.80 – 7.55 (m, 3H), 7.29 (d, *J* = 2.0 Hz, 1H), 7.19 (d, *J* = 2.4 Hz, 1H), 7.17 – 7.10 (m, 2H), 7.08 (dd, *J* = 9.2, 2.4 Hz, 1H), 6.90 (dd, *J* = 8.9, 5.3 Hz, 1H), 6.65 (td, *J* = 9.2, 2.4 Hz, 1H), 3.92 (s, 3H), 1.90 (s, 3H).


**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.1, 160.2 (d, *J* = 240 Hz), 158.2, 137.2 (d, *J* = 10 Hz), 136.4, 133.9, 129.8, 129.1, 127.6, 126.6, 126.4, 123.9 (d, *J* = 4 Hz), 122.6, 122.2 (d, *J* = 10 Hz), 119.3, 116.4, 108.9 (d, *J* = 24 Hz), 105.8, 97.9 (d, *J* = 24 Hz), 55.7, 55.6, 23.1.

**$^{19}\text{F NMR}$  (376 MHz,  $\text{CDCl}_3$ ):**  $\delta$  -120.5 (s, 1F).

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{22}\text{H}_{18}\text{FNO}_2$  [ $\text{M}+\text{H}]^+$ : 348.1394; found: 348.1394.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 25% (1.66%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 9.63$  min;  $t_{\text{minor}} = 9.86$  min; **General Procedure A:** 85% ee.  $[\alpha]_D^{25} = +11.3$  (*c* 1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(6-Methoxy-1*H*-indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4i**



Following the general procedure A, the product was isolated in 20% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.99 (s, 1H), 8.13 (bs, 1H), 7.74 – 7.60 (m, 3H), 7.29 (dd, *J* = 8.6, 2.1 Hz, 1H), 7.17 – 7.08 (m, 3H), 6.91 – 6.84 (m, 2H), 6.56 (dd, *J* = 8.6, 2.1 Hz, 1H), 3.92 (s, 3H), 3.81 (s, 3H), 1.89 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.1, 158.0, 156.7, 137.9, 136.7, 133.7, 129.7, 129.0, 127.4, 126.6, 126.3, 122.2, 121.8, 120.2, 119.1, 116.0, 109.9, 105.7, 94.8, 55.7, 55.5, 23.1.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{23}\text{H}_{21}\text{NO}_3$  [ $\text{M}+\text{H}]^+$ : 360.1594; found: 360.1596.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0  $\text{mL}\cdot\text{min}^{-1}$ ;  $t_{\text{major}} = 4.71$  min;  $t_{\text{minor}} = 4.99$  min; **General Procedure A:** 85% ee.  $[\alpha]_D^{27} = +39.6$  (*c* 0.3,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(6-Methoxynaphthalen-2-yl)-2-(2-phenyl-1H-indol-3-yl)propanal, 4j**



**4j**

Following the general procedure A, the product was isolated in 53% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.57 (s, 1H), 8.13 (bs, 1H), 7.73 (d,  $J = 1.9$  Hz, 1H), 7.66 (d,  $J = 8.7$  Hz, 1H), 7.60 (d,  $J = 8.7$  Hz, 1H), 7.43 (ddd,  $J = 5.7, 4.2, 2.7$  Hz, 2H), 7.40 – 7.29 (m, 5H), 7.21 – 7.10 (m, 2H), 7.07 (d,  $J = 2.5$  Hz, 1H), 6.90 – 6.78 (m, 2H), 3.90 (s, 3H), 2.03 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.1, 158.0, 136.1, 136.1, 135.2, 133.6, 133.2, 130.3 (2C), 129.8, 129.1 (2C), 128.4 (2C), 127.3 (2C), 127.1, 127.0, 122.5, 121.4, 119.9, 119.0, 114.4, 110.9, 105.5, 56.0, 55.4, 22.2.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{28}\text{H}_{23}\text{NO}_2$  [ $\text{M}+\text{H}]^+$ : 406.1802; found: 406.1805.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 4.90$  min;  $t_{\text{minor}} = 4.39$  min; **General Procedure A:** 89% ee.  $[\alpha]_D^{25} = -94.8$  ( $c$  0.5,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(6-Methoxynaphthalen-2-yl)-2-(1,6,7,8-tetrahydrocyclopenta[g]indol-3-yl)propanal, 4k**



**4k**

Following the general procedure A, the product was isolated in 40% yield as a dark red oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  10.03 (s, 1H), 8.09 (bs, 1H), 7.79 – 7.53 (m, 3H), 7.31 (dd,  $J = 8.6, 2.0$  Hz, 1H), 7.14 (dt,  $J = 11.3, 2.3$  Hz, 3H), 6.83 (s, 2H), 3.92 (s, 3H), 3.03 (dt,  $J = 25.0, 7.4$  Hz, 4H), 2.21 (p,  $J = 7.4$  Hz, 2H), 1.91 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.2, 158.0, 139.1, 136.8, 134.3, 133.7, 129.7, 129.0, 127.5, 126.7, 126.3, 125.9, 124.5, 122.7, 119.3, 119.1, 116.9, 116.6, 105.7, 55.8, 55.5, 33.2, 30.0, 25.5, 23.1.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{25}\text{H}_{23}\text{NO}_2$  [ $\text{M}+\text{H}]^+$ : 370.1802; found: 370.1806.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 4.73$  min;  $t_{\text{minor}} = 5.27$  min; **General Procedure A:** 91% ee.  $[\alpha]_D^{25} = +45.6$  ( $c$  0.5,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(1H-Benzo[g]indol-3-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4l**



**4l**

Following the general procedure A, the product was isolated in 29% yield as a grey solid by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  10.07 (s, 1H), 9.00 (bs, 1H), 8.04 (dd,  $J = 8.2, 1.1$  Hz, 1H), 7.85 (d,  $J = 8.0$  Hz, 1H), 7.72 – 7.64 (m, 3H), 7.55 (ddd,  $J = 8.2, 6.9, 1.3$  Hz, 1H), 7.43 (ddd,  $J = 8.2, 7.0, 1.3$  Hz, 1H), 7.32 (dd,  $J = 8.7, 2.0$  Hz, 1H), 7.28 (d,  $J = 2.4$  Hz, 1H), 7.16 – 6.99 (m, 4H), 3.92 (s, 3H), 1.96 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.1, 158.0, 136.8, 133.8, 131.9, 130.4, 129.7, 129.0, 127.5, 126.6, 126.4, 125.8, 124.5, 122.0, 121.8, 121.4, 120.7, 120.7, 119.4, 119.2, 117.9, 105.7, 55.9, 55.5, 23.3.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{26}\text{H}_{21}\text{NO}_2$  [ $\text{M}+\text{H}]^+$ : 380.1645; found: 380.1647.

**UPC<sup>2</sup>:** Chiralpak ID-3 column [ $\text{CO}_2/\text{iPrOH}$  gradient, 1%  $\text{iPrOH}$  (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 5.01$  min;  $t_{\text{minor}} = 4.79$  min; **General Procedure A:** 89% ee.  $[\alpha]_D^{26} = +48.6$  ( $c$  0.33,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(1H-Benzo[g]indol-2-yl)-2-(6-methoxynaphthalen-2-yl)propanal, 4l'**



Following the general procedure A, the product was isolated in 53% yield as a grey solid by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.97 (s, 1H), 8.94 (s, 1H), 8.03 – 7.84 (m, 2H), 7.76 (d,  $J$  = 8.6 Hz, 1H), 7.73 – 7.63 (m, 3H), 7.54 (d,  $J$  = 8.6 Hz, 1H), 7.48 (ddd,  $J$  = 8.3, 6.9, 1.4 Hz, 1H), 7.45 – 7.39 (m, 1H), 7.31 (dd,  $J$  = 8.6, 2.0 Hz, 1H), 7.20 – 7.09 (m, 2H), 6.62 (d,  $J$  = 2.3 Hz, 1H), 3.93 (s, 3H), 2.04 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  198.8, 158.4, 136.0, 135.5, 134.1, 131.4, 130.6, 129.7, 129.0, 128.9, 128.0, 126.6, 126.2, 125.7, 124.2, 124.1, 121.6, 121.2, 120.6, 119.6, 119.6, 105.7, 104.5, 56.2, 55.5, 22.8.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{26}\text{H}_{21}\text{NO}_2$  [ $\text{M}+\text{H}$ ]<sup>+</sup>: 380.1645; found: 380.1647.

**UPC<sup>2</sup>:** Chiralpak IDB-3 column [ $\text{CO}_2$ /iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 4.73$  min;  $t_{\text{minor}} = 4.61$  min; **General Procedure A:** 47% ee.  $[\alpha]_D^{25} = -12.8$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(1H-Indol-3-yl)-2-(naphthalen-2-yl)propanal, 4m**



Following the general procedure A, the product was isolated in 65% yield as a light yellow oil by FC on Iatrobeads using pentane: $\text{CH}_2\text{Cl}_2$  2:1 to 1:2 as eluent.


**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  10.06 (s, 1H), 8.28 (bs, 1H), 7.86 – 7.70 (m, 4H), 7.52 – 7.45 (m, 2H), 7.42 (dt,  $J$  = 8.2, 0.9 Hz, 1H), 7.35 (dd,  $J$  = 8.6, 1.9 Hz, 1H), 7.22 (d,  $J$  = 2.6 Hz, 1H), 7.18 (ddd,  $J$  = 8.2, 7.0, 1.2 Hz, 1H), 7.03 (dd,  $J$  = 8.2, 1.1 Hz, 1H), 6.90 (ddd,  $J$  = 8.1, 7.0, 1.0 Hz, 1H), 1.94 (s, 3H).

**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.0, 139.1, 137.1, 133.5, 132.6, 128.6, 128.2, 127.7, 126.4, 126.3, 126.2, 126.1, 125.9, 123.6, 122.5, 121.2, 120.0, 115.8, 111.6, 56.0, 23.1.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{21}\text{H}_{17}\text{NO}$  [ $\text{M}+\text{H}$ ]<sup>+</sup>: 300.1383; found: 300.1385.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2$ /MeOH gradient, 1% MeOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 3.96$  min;  $t_{\text{minor}} = 4.32$ ; **General Procedure A:** 92% ee.  $[\alpha]_D^{24} = +28.0$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(1H-Indol-3-yl)-2-(4-methoxyphenyl)propanal, 4n**



Following the general procedure A, the product was isolated in 60% yield as a light yellow oil by FC on Iatrobeads using  $\text{CH}_2\text{Cl}_2$  as eluent.

**$^1\text{H NMR}$  (400 MHz,  $\text{CDCl}_3$ ):**  $\delta$  9.91 (s, 1H), 8.24 (bs, 1H), 7.40 (dt,  $J$  = 8.3, 1.0 Hz, 1H), 7.22 – 7.11 (m, 4H), 7.06 (dd,  $J$  = 8.3, 1.0 Hz, 1H), 6.96 (ddd,  $J$  = 8.0, 6.9, 1.0 Hz, 1H), 6.91 – 6.83 (m, 2H), 3.81 (s, 3H), 1.83 (s, 3H).


**$^{13}\text{C NMR}$  (100 MHz,  $\text{CDCl}_3$ ):**  $\delta$  199.2, 158.8, 137.1, 133.2, 129.1 (2C), 125.9, 123.3, 122.5, 121.3, 119.8, 116.3, 114.2 (2C), 111.6, 55.4, 55.1, 23.1.

**HRMS (ESI+)**  $m/z$  calcd. for  $\text{C}_{18}\text{H}_{17}\text{NO}_2$  [ $\text{M}+\text{H}$ ]<sup>+</sup>: 280.1332; found: 280.1339.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [ $\text{CO}_2$ /iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>;  $t_{\text{major}} = 3.69$  min;  $t_{\text{minor}} = 3.91$  min;

**General Procedure A:** 86% ee.  $[\alpha]_D^{25} = +19.8$  ( $c$  1.0,  $\text{CH}_2\text{Cl}_2$ ).

**(R)-2-(1H-Indol-3-yl)-2-(*p*-tolyl)propanal, 4o**



Following the general procedure A, the product was isolated in 47% yield as a light yellow oil by FC on Iatrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 2:1 to 1:2 as eluent.

**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.93 (s, 1H), 8.22 (bs, 1H), 7.45 – 7.35 (m, 1H), 7.22 – 7.10 (m, 6H), 7.05 (dd, *J* = 8.1, 1.1 Hz, 1H), 6.99 – 6.90 (m, 1H), 2.35 (s, 3H), 1.83 (s, 3H).


**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 199.2, 138.3, 137.1, 137.0, 129.6 (2C), 127.8 (2C), 125.9, 123.3, 122.5, 121.3, 119.8, 116.2, 111.5, 55.5, 23.1, 21.2.

**HRMS (ESI+)** *m/z* calcd. for C<sub>18</sub>H<sub>17</sub>NO [M+H]<sup>+</sup>: 264.1383; found: 264.1386.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.57 min; t<sub>minor</sub> = 3.82 min;

**General Procedure A:** 94% ee. [α]<sub>D</sub><sup>24</sup> = +34.7 (*c* 0.38, CH<sub>2</sub>Cl<sub>2</sub>).

**(R)-2-(1H-Indol-3-yl)-2-phenylpropanal, 4p**



Following the general procedure A, the product was isolated in 20% yield as a dark red oil by FC on Iatrobeads using CH<sub>2</sub>Cl<sub>2</sub> as eluent.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.96 (s, 1H), 8.24 (bs, 1H), 7.41 (dt, *J* = 8.2, 1.0 Hz, 1H), 7.36 – 7.27 (m, 3H), 7.25 – 7.21 (m, 2H), 7.20 – 7.14 (m, 2H), 7.05 – 6.99 (m, 1H), 6.95 (ddd, *J* = 8.2, 6.9, 1.0 Hz, 1H), 1.85 (s, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 199.1, 141.4, 137.1, 128.9 (2C), 127.9 (2C), 127.3, 125.9, 123.4, 122.5, 121.2, 119.9, 116.0, 111.6, 55.8, 23.1.

**HRMS (ESI+)** *m/z* calcd. for C<sub>17</sub>H<sub>15</sub>NO<sub>2</sub> [M+H]<sup>+</sup>: 250.1226; found: 250.1226.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.34 min; t<sub>minor</sub> = 3.60 min; **General Procedure A:** 66% ee. [α]<sub>D</sub><sup>25</sup> = +352.0 (*c* 0.07, CH<sub>2</sub>Cl<sub>2</sub>).

**(R)-2-(3-Bromo-4-methoxyphenyl)-2-(1H-indol-3-yl)propanal, 4q**



Following the general procedure A, the product was isolated in 42% yield as a dark yellow oil by FC on Iatrobeads using CH<sub>2</sub>Cl<sub>2</sub> as eluent.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.86 (s, 1H), 8.25 (bs, 1H), 7.43 (d, *J* = 2.3 Hz, 1H), 7.43 – 7.39 (m, 1H), 7.24 – 7.15 (m, 1H), 7.16 (d, *J* = 2.6 Hz, 1H), 7.12 (dd, *J* = 8.6, 2.3 Hz, 1H), 7.08 – 7.03 (m, 1H), 7.02 – 6.93 (m, 1H), 6.85 (d, *J* = 8.6 Hz, 1H), 3.88 (s, 3H), 1.82 (s, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.5, 155.1, 137.1, 134.8, 132.7, 128.2, 125.6, 123.3, 122.6, 121.1, 120.0, 115.5, 112.0 (2C), 111.6, 56.4, 54.9, 23.1.

**HRMS (ESI+)** *m/z* calcd. for C<sub>18</sub>H<sub>16</sub>BrNO<sub>2</sub> [M+H]<sup>+</sup>: 358.0437; found: 358.0443.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.87 min; t<sub>minor</sub> = 4.01 min; **General Procedure A:** 89% ee. [α]<sub>D</sub><sup>25</sup> = +5.0 (*c* 0.36, CH<sub>2</sub>Cl<sub>2</sub>).

**(R)-2-(3-Chloro-4-methoxyphenyl)-2-(1H-indol-3-yl)propanal, 4r**



**4r**

Following the general procedure A, the product was isolated in 88% yield as a light red oil by FC on Iatrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 1:1 to 1:3 as eluent. Following the general procedure C, the product was isolated in 49% yield.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.87 (s, 1H), 8.29 (bs, 1H), 7.40 (d, J = 8.2 Hz, 1H), 7.28 – 7.22 (m, 1H), 7.21 – 7.17 (m, 1H), 7.15 (d, J = 2.6 Hz, 1H), 7.11 – 7.04 (m, 2H), 7.00 – 6.96 (m, 1H), 6.87 (d, J = 8.6 Hz, 1H), 3.89 (s, 3H), 1.82 (s, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.6, 154.2, 137.1, 134.4, 129.7, 127.4, 125.6, 123.4, 122.7, 122.6, 121.0, 120.0, 115.5, 112.2, 111.7, 56.3, 54.9, 23.1.

**HRMS (ESI+)** m/z calcd. for C<sub>18</sub>H<sub>16</sub>CINO<sub>2</sub> [M+H]<sup>+</sup>: 314.0942; found: 314.0948.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.83 min; t<sub>minor</sub> = 3.96 min; **General Procedure A:** 91% ee. [α]<sup>25</sup><sub>D</sub> = +13.8 (c 1.0, CH<sub>2</sub>Cl<sub>2</sub>). **General Procedure B:** 87% ee.

**(R)-2-(1H-Indol-3-yl)-2-(4-methoxyphenyl)butanal, 4s**



**4s**

Following the general procedure A, the product was isolated in 56% yield as a light red oil by FC on Iatrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 1:1 to 1:6 as eluent.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.76 (s, 1H), 8.26 (bs, 1H), 7.38 (d, J = 8.2, 1H), 7.30 (d, J = 2.6 Hz, 1H), 7.21 – 7.11 (m, 3H), 6.99 – 6.91 (m, 2H), 6.90 – 6.85 (m, 2H), 3.81 (s, 3H), 2.45 – 2.38 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.5, 158.7, 136.8, 131.1, 130.0 (2C), 126.2, 124.1, 122.4, 121.4, 119.7, 114.3, 114.0 (2C), 111.4, 59.3, 55.4, 27.4, 9.5.

**HRMS (ESI+)** m/z calcd. for C<sub>19</sub>H<sub>19</sub>NO<sub>2</sub> [M+Na]<sup>+</sup>: 316.1308; found: 316.1311.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.78 min; t<sub>minor</sub> = 4.11 min; **General Procedure A:** 56% ee. [α]<sup>25</sup><sub>D</sub> = +25.2 (c 0.5, CH<sub>2</sub>Cl<sub>2</sub>).

**(R)-2-(1H-indol-3-yl)-2-(4-methoxyphenyl)pentanal, 4t**



**4t**

Following the general procedure A, the product was isolated in 42% yield as a light yellow oil by FC on Iatrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 1:1 to 1:3 as eluent.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.74 (s, 1H), 8.23 (bs, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.30 (d, J = 2.6 Hz, 1H), 7.19 – 7.15 (m, 3H), 6.96 – 6.91 (m, 2H), 6.90 – 6.85 (m, 2H), 3.80 (s, 3H), 2.37 – 2.19 (m, 2H), 1.21 – 1.04 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.4, 158.7, 136.8, 131.3, 129.9 (2C), 126.2, 124.0, 122.4, 121.4, 119.7, 114.6, 114.0 (2C), 111.4, 58.9, 55.4, 37.0, 18.4, 14.7.

**HRMS (ESI+)** m/z calcd. for C<sub>20</sub>H<sub>21</sub>NO<sub>2</sub> [M+H]<sup>+</sup>: 308.1645; found: 308.1649.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/MeOH gradient, 1% MeOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.41 min; t<sub>minor</sub> = 3.51 min; **General Procedure A:** 49% ee. [α]<sup>26</sup><sub>D</sub> = +19.2 (c 0.5, CH<sub>2</sub>Cl<sub>2</sub>).

**(R)-2-Cyclopropyl-2-(1H-indol-3-yl)-2-(4-methoxyphenyl)acetaldehyde, 4u**



Following the general procedure A, the product was isolated in 85% yield as a light redbrown oil by FC on latrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 1:1 to 1:3 to 1:6 as eluent. Following the general procedure C, the product was isolated in 46% yield.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 9.90 (s, 1H), 8.27 (bs, 1H), 7.39 – 7.36 (m, 2H), 7.17 – 7.11 (m, 3H), 6.92 – 6.83 (m, 4H), 3.80 (s, 3H), 1.80 (tt, *J* = 8.4, 5.5 Hz, 1H), 0.65 – 0.49 (m, 2H), 0.07 – 0.02 (m, 2H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.7, 158.9, 136.8, 131.0 (2C), 129.1, 126.3, 125.0, 122.3, 121.3, 119.8, 114.2, 113.6 (2C), 111.4, 59.4, 55.3, 14.9, 1.4, 0.8.

**HRMS (ESI+)** *m/z* calcd. for C<sub>20</sub>H<sub>19</sub>NO<sub>2</sub> [M+H]<sup>+</sup>: 306.1489; found: 306.1491.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/MeOH gradient, 1% MeOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 3.76 min; t<sub>minor</sub> = 3.93 min; **General Procedure A:** 47% ee. [α]<sub>D</sub><sup>25</sup> = +11.6 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>). **General Procedure B:** 53% ee.

**(R)-2-(6-Methoxynaphthalen-2-yl)-2-(1-methyl-1H-indol-3-yl)propanal, 4v**



Following the general procedure A, the product was isolated in 23% yield as a yellow oil by FC on latrobeads using pentane:CH<sub>2</sub>Cl<sub>2</sub> 1:1 to 1:3 as eluent.


**<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):** δ 10.02 (s, 1H), 7.71 – 7.66 (m, 3H), 7.36 – 7.31 (m, 2H), 7.23 – 7.13 (m, 3H), 7.05 – 7.01 (m, 2H), 6.92 – 6.82 (m, 1H), 3.92 (s, 3H), 3.83 (s, 3H), 1.91 (s, 3H).

**<sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>):** δ 198.9, 158.0, 137.9, 136.8, 133.7, 129.7, 129.0, 128.2, 127.4, 126.6, 126.4, 126.2, 122.0, 121.3, 119.4, 119.1, 114.1, 109.7, 105.6, 55.7, 55.5, 33.1, 23.2.


**HRMS (ESI+)** *m/z* calcd. for C<sub>23</sub>H<sub>21</sub>NO<sub>2</sub> [M+H]<sup>+</sup>: 344.1645; found: 344.1653.

**UPC<sup>2</sup>:** Chiralpak IC-3 column [CO<sub>2</sub>/iPrOH gradient, 1% iPrOH (0.5 min), then gradient from 1% to 40% (10%/min), 120 bar, 40 °C], 3.0 mL·min<sup>-1</sup>; t<sub>major</sub> = 4.65 min; t<sub>minor</sub> = 5.02 min; **General Procedure A:** 80% ee. [α]<sub>D</sub><sup>24</sup> = +33.2 (*c* 1.0, CH<sub>2</sub>Cl<sub>2</sub>).

## 5. Homo-coupling of **1a** using **3d** or **3g**



A flame dried 4 mL glass vial equipped with a magnetic stirring bar was charged with **3d** or **3g** (0.04 mmol, 0.40 equiv.), **1a** (0.20 mmol, 2.0 equiv.),  $p\text{-NO}_2\text{-C}_6\text{H}_4\text{CO}_2\text{H}$  (0.150 mmol, 1.50 equiv.), and dry  $\text{CH}_2\text{Cl}_2$  (0.4 mL). To the resulting mixture DDQ (0.150 mmol, 1.50 equiv.) was added. The vial was flushed with Ar, and the reaction mixture was stirred for 10 h.




**Figure S1.** NMR of aldehyde region from the homo-coupling of **1a**. ■ = **5a** (homo-coupling), ● = **1a**.

## 6. Radical Clock and Trapping Experiments


### 6.1 Allylamine Trapping Experiment

To a flame-dried 4 mL glass vial equipped with a magnetic stirring bar, reagents and solvent were added in the following order; allylamine (0.15 mmol, 1.5 equiv.), indole **2a** (0.5 mmol, 5 equiv.), aldehyde **1a** (0.1 mmol, 1 equiv.), trimethoxy benzene (0.033 mmol), and anhyd. CH<sub>2</sub>Cl<sub>2</sub> (0.4 mL). The vial was quickly flushed with Ar and the first portion of DDQ (0.05 mmol, 0.5 equiv.) was added. After 15 min. of stirring, the last portion of DDQ (0.06 mmol, 0.6 equiv.) was added and the reaction was stirred for 16 h at RT to afford the oxidative cross-coupling products **4a**.




### 6.2 Cyclopropyl Radical Clock Experiment

To a flame-dried 4 mL glass vial equipped with a magnetic stirring bar, reagents and solvent were added in the following order; catalyst **3f** (0.020 mmol, 20 mol%), *p*-CN-benzoic acid (0.15 mmol, 1.5 equiv.), indole **2a** (0.5 mmol, 5 equiv.), aldehyde **1u** (0.1 mmol, 1 equiv.) and anhyd. CH<sub>2</sub>Cl<sub>2</sub> (0.4 mL). The vial was quickly flushed with Ar and the first portion of DDQ (0.05 mmol, 0.5 equiv.) was added. After 15 min. of stirring, the last portion of DDQ (0.06 mmol, 0.6 equiv.) was added and the reaction was stirred for 3 h at RT to afford the chiral oxidative cross-coupling products **4u**.



### 6.3 BHT Trapping Experiment


To a flame-dried 4 mL glass vial equipped with a magnetic stirring bar, reagents and solvent were added in the following order; **3h** (0.010 mmol, 20 mol%), indole **2a** (0.25 mmol, 5 equiv.), aldehyde **1a** (0.050 mmol, 1 equiv.), BHT (0.075 mmol, 1.5 equiv.), trimethoxy benzene (0.033 mmol), and anhyd.  $\text{CH}_2\text{Cl}_2$  (0.2 mL). The vial was quickly flushed with Ar and the first portion of DDQ (0.025 mmol, 0.5 equiv.) was added. After 15 min. of stirring, the last portion of DDQ (0.03 mmol, 0.6 equiv.) was added and the reaction was stirred for 16 h at RT to afford the oxidative cross-coupling products **4a**.



## 7. Crystallographic Data

Crystallographic data for the crystal structure of **4g**

Item	Value
Molecular formula	C <sub>22</sub> H <sub>18</sub> BrNO <sub>2</sub>
Formula weight	408.28
Crystal system	Orthorhombic
Space Group	P2 <sub>1</sub> 2 <sub>1</sub> 2 <sub>1</sub>
a (Å)	9.3465
b (Å)	10.4901
c (Å)	18.9441
α (°)	90
β (°)	90
γ (°)	90
Volume (Å <sup>3</sup> )	1857.4
Z	4
T (K)	100
ρ (g cm <sup>-1</sup> )	1.46
λ (Å)	0.56086
μ (mm <sup>-1</sup> )	1.2
# measured refl	84357
# unique refl	6463
R <sub>int</sub>	0.0404
# parameters	278
R(F <sup>2</sup> ), all refl	0.0237
R <sub>w</sub> (F <sup>2</sup> ), all refl	0.05
Goodness of fit	1.053



Crystal data for **4g**: C<sub>22</sub>H<sub>18</sub>BrNO<sub>2</sub>,  $M = 408.28$ , orthorhombic, space group P 2<sub>1</sub>2<sub>1</sub>2<sub>1</sub> (no. 19),  $a = 9.3465(7)$  Å,  $b = 10.4901(8)$  Å,  $c = 18.9441(15)$  Å, Flack parameter = 0.009,  $V = 1857.4(2)$  Å<sup>3</sup>,  $T = 100$  K,  $Z = 4$ ,  $d_c = 1.46$  g cm<sup>-3</sup>,  $\mu(\text{Mo K}\alpha, \lambda = 0.56086$  Å) = 1.2 mm<sup>-1</sup>, 84357 reflections collected, 6463 unique [ $R_{\text{int}} = 0.0404$ ], which were used in all calculations. Refinement on F<sup>2</sup>, final R(F) = 0.0237, R<sub>w</sub>(F2) = 0.05. CCDC 1863137.

## 8. Computational Studies

Full *Gaussian09* Reference

Gaussian 09, Revision D.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and D. J. Fox, Gaussian, Inc., Wallingford CT, **2013**.

### Computational methods

All calculations were performed using *Gaussian09*, and were analyzed using *GaussView5*. All minima were found using DFT at the B3LYP/6-31+G(d,p) level of theory<sup>7</sup> with implicit SMD model of solvation in dichloromethane (smd,solvent = dichloromethane)<sup>8</sup> for all structures (T = 298 K). Minima were determined to be stationary points by the inclusion of a frequency calculation indicating no imaginary frequencies.

---


7. a) Becke, A. D. *J. Chem. Phys.* 1993, **98**, 1372; b) Becke, A. D. *J. Chem. Phys.* 1993, **98**, 5648; c) Lee, C.; Yang, W.; Parr, R. G. *Phys. Rev. B* 1988, **37**, 785-789.

8. Manerich, A. V.; Cramer, C. J., Truhlar, D. G. *J. Phys. Chem. B.* 2009, **113**, 6378.

## 8.1 Ground state computations (geometric coordinates and DFT energies)

**Table S2.** Geometric coordinates and DFT energies for water ( $\text{H}_2\text{O}$ ).

$\text{H}_2\text{O}$





*No imaginary frequencies found*

$G = -47966.2708 \text{ kcal/mol}$

Zero-point correction=	0.020986 (Hartree/Particle)
Thermal correction to Energy=	0.023822
Thermal correction to Enthalpy=	0.024766
Thermal correction to Gibbs Free Energy=	0.003325
Sum of electronic and zero-point Energies=	-76.421454
Sum of electronic and thermal Energies=	-76.418618
Sum of electronic and thermal Enthalpies=	-76.417673
Sum of electronic and thermal Free Energies=	-76.439115

Center Number	Atomic Number	Forces (Hartrees/Bohr)		
		X	Y	Z
1	8	-0.000001835	-0.000055831	-0.000003344
2	1	0.000024858	0.000027091	0.000002298
3	1	-0.000023022	0.000028740	0.000001045

**Table S3.** Geometric coordinates and DFT energies for aldehyde **xx**




No imaginary frequencies found

G = -434377.1851 kcal/mol

Zero-point correction=	0.244860 (Hartree/Particle)
Thermal correction to Energy=	0.259341
Thermal correction to Enthalpy=	0.260285
Thermal correction to Gibbs Free Energy=	0.202949
Sum of electronic and zero-point Energies=	-692.182167
Sum of electronic and thermal Energies=	-692.167686
Sum of electronic and thermal Enthalpies=	-692.166742
Sum of electronic and thermal Free Energies=	-692.224078

Center Number	Atomic Number	Forces (Hartrees/Bohr)		
		X	Y	Z
1	6	-0.000005446	0.000007758	0.000007269
2	6	0.000006660	-0.000000827	0.000002799
3	6	-0.000008061	0.000001933	-0.000001590
4	6	-0.000007553	-0.000001743	0.000003292
5	6	0.000006171	0.000000563	0.000007762
6	6	-0.000002796	-0.000005146	0.000009075
7	1	-0.000001415	-0.000000076	-0.000008115
8	1	-0.000001119	0.000000404	-0.000001750
9	6	0.000008943	-0.000000105	-0.000005721
10	6	0.000012020	0.000001260	-0.000001575
11	1	-0.000000261	0.000000215	0.000010690
12	1	-0.000000644	0.000000300	0.000012046
13	6	-0.000004434	0.000006741	-0.000002836
14	6	-0.000005865	-0.000008804	-0.000008627
15	1	-0.000000822	-0.000000462	0.000004748
16	1	0.000002323	0.000001852	-0.000010340
17	8	-0.000001907	0.000000854	0.000004202
18	6	0.000002013	-0.000001141	0.000010686
19	1	-0.000001176	0.000001769	0.000014347
20	1	0.000001044	0.000000191	0.000014177
21	1	-0.000003654	0.000003854	0.000013691
22	6	-0.000001363	-0.000000882	-0.000007878
23	1	0.000001360	-0.000000479	-0.000001218
24	6	-0.000004181	-0.000000416	-0.000014497
25	1	-0.000005088	0.000004100	-0.000007128
26	1	-0.000001168	0.000001970	-0.000008278
27	1	-0.000001580	0.000001563	-0.000012247
28	6	0.000002592	-0.000016266	-0.000015669
29	1	0.000006867	-0.000001101	-0.000007058
30	8	0.000008540	0.000002123	-0.000000256

**Table S4.** Geometric coordinates and DFT energies for aminocatalyst **3f**.



No imaginary frequencies found

G = -605913.9896 kcal/mol

Zero-point correction=

0.476073 (Hartree/Particle)

Thermal correction to Energy=

0.499369

Thermal correction to Enthalpy=

0.500314

Thermal correction to Gibbs Free Energy=

0.422277

Sum of electronic and zero-point Energies=

-965.531569

Sum of electronic and thermal Energies=


-965.508273

Sum of electronic and thermal Enthalpies=

-965.507329

Sum of electronic and thermal Free Energies=

-965.585365




Center Number	Atomic Number	Forces (Hartrees/Bohr)		
		X	Y	Z
1	6	-0.000000542	0.000005240	0.000006852
2	1	-0.000000009	-0.000000828	0.000000728
3	1	-0.000001302	-0.000001718	0.000000806
4	6	-0.000002125	-0.000000622	0.000000818
5	1	-0.000002447	0.000000503	0.000000335
6	6	-0.000004213	-0.000003057	0.000004266
7	6	-0.000000664	0.000002111	0.000003081
8	1	-0.000001767	0.000001192	0.000002550
9	1	-0.000001818	0.000000483	0.000003532
10	1	-0.000002463	-0.000001648	0.000004037
11	6	0.000000073	-0.000001529	0.000003993
12	1	-0.000001955	-0.000000710	0.000003035
13	1	-0.000001713	-0.000002811	0.000002362
14	1	-0.000002388	-0.000001034	0.000004480
15	6	0.000000618	-0.000003226	-0.000001312
16	1	-0.000001364	-0.000002999	0.000003286
17	1	-0.000001260	-0.000002742	0.000003469
18	1	0.000000044	-0.000003642	0.000002371
19	6	-0.000000021	0.000002192	0.000002601
20	6	0.000003874	-0.000003253	0.000002495
21	6	0.000001809	0.000005244	-0.000002192
22	1	-0.000000388	0.000002520	-0.000002450
23	6	-0.000001210	0.000001110	-0.000001669
24	1	0.000002411	0.000000303	0.000000319
25	1	0.000000404	0.000000180	-0.000002008
26	1	0.000001984	0.000001368	-0.000004979
27	1	0.000001787	-0.000000587	-0.000004036
28	1	0.000002036	0.000002526	-0.000002248
29	7	-0.000006104	-0.000006528	-0.000010101
30	6	0.000005367	-0.000001984	-0.000000690
31	6	-0.000000022	-0.000000855	-0.000004767

32	6	0.000001772	-0.000001334	-0.000001285
33	6	0.000000914	-0.000005343	-0.000003452
34	1	0.000002479	-0.000002135	-0.000001468
35	6	0.000003063	-0.000001483	-0.000005431
36	1	0.000000508	-0.000000666	-0.000003293
37	6	0.000004556	-0.000002055	-0.000002815
38	1	0.000003287	-0.000004038	-0.000002556
39	1	0.000001962	-0.000003228	-0.000003902
40	1	0.000002422	-0.000004822	-0.000003320
41	6	0.000005635	0.000000044	0.000002193
42	6	-0.000000705	0.000006754	-0.000001937
43	6	-0.000003752	0.000000259	-0.000001300
44	6	-0.000002815	0.000002756	0.000002929
45	1	-0.000001500	0.000004137	0.00000332
46	6	0.000000947	0.000004948	-0.000002379
47	1	-0.000000405	0.000003045	-0.000001077
48	6	-0.000003290	0.000003616	0.000003765
49	1	-0.000002303	0.000005962	0.00000628
50	1	-0.000000589	0.000002905	0.000001369
51	1	-0.000000854	0.000004919	0.000001670
52	7	0.000001506	0.000001503	0.000003299
53	1	0.000000236	-0.000000677	-0.000000417
54	1	0.000000296	-0.000000264	-0.000000519


---


**Table S5.** Geometric coordinates and DFT energies for enamine.






28	1	-0.000002200	-0.00000725	-0.00000713
29	1	-0.000001592	0.000001116	0.00000386
30	1	-0.000003943	-0.000000206	-0.000001328
31	6	-0.000003334	0.000001083	-0.000003068
32	1	-0.000003485	-0.000001163	-0.000002013
33	1	-0.000001936	-0.000000738	-0.000001115
34	1	-0.000002805	-0.000001929	-0.000003072
35	6	0.000008152	0.000002332	-0.00000085
36	6	0.000002550	-0.000005638	0.000003298
37	6	0.000000584	0.000000314	-0.000003514
38	1	0.000000088	-0.000002835	-0.000002288
39	6	0.000005088	-0.000004869	-0.000004788
40	1	0.000002480	-0.00000142	-0.000001622
41	1	0.000002398	-0.000001089	0.00000417
42	1	0.000003906	-0.000001592	-0.000001615
43	1	0.000003206	-0.000001738	-0.000001341
44	1	0.000004074	-0.000000371	-0.000002827
45	7	0.000007213	0.000005067	-0.000005035
46	6	0.000003716	0.000002586	-0.000005312
47	6	0.000003440	-0.000004676	-0.00000448
48	6	-0.000000703	0.000003547	-0.000005180
49	6	0.000000076	0.000001617	-0.000002704
50	1	0.000002323	-0.000002728	-0.000002284
51	6	-0.000000234	-0.000004934	0.000003114
52	1	0.000002626	-0.000000502	0.000004003
53	6	0.000006152	0.000000386	-0.00000630
54	1	0.000002552	-0.000001189	-0.000001394
55	1	0.000003576	0.000000575	0.00000553
56	1	0.000003634	-0.000000201	-0.00000503
57	6	-0.000003499	-0.000001946	-0.000002642
58	6	0.000004345	-0.000001657	-0.000003269
59	6	0.000001294	-0.000000520	-0.000006079
60	6	-0.000002037	-0.000001980	-0.000004278
61	1	-0.000000733	-0.000000682	-0.000001102
62	6	-0.000001146	-0.000002722	-0.000002985
63	1	0.000001213	0.000000041	-0.000004351
64	6	0.000003698	-0.000002733	-0.000004640
65	1	0.000000062	-0.000001924	-0.000003259
66	1	0.000001580	-0.000002816	-0.000006003
67	1	-0.000000128	-0.000003944	-0.000005984
68	6	-0.000001544	-0.000001630	0.000004780
69	6	-0.000000510	0.000005644	0.000002845
70	6	-0.000006069	0.000003555	0.000009519
71	1	0.000001425	0.000004573	0.000006266
72	6	-0.000004869	0.000005027	0.000005252
73	6	0.000003398	0.000009448	0.000002486
74	1	-0.000003364	0.000001384	0.000006829
75	6	0.000004912	-0.000000709	0.000008317
76	1	-0.000002765	0.000003499	0.000004018
77	8	-0.000001094	0.000003897	0.000009236
78	1	-0.000000609	0.000003780	0.000008824


## 9. NMR Spectra


















**4c**































**4i**





























**4p**





















**4v**




## 9. UPC-traces







	Retention Time (min)	% Area
1	4.517	49.53
2	4.759	50.47





	Retention Time (min)	% Area
1	4.468	96.45
2	4.710	3.55




	Retention Time (min)	% Area
1	4.085	54.33
2	4.209	45.67




	Retention Time (min)	% Area
1	3.938	94.05
2	4.044	5.95










	Retention Time (min)	% Area
1	8.658	49.08
2	8.830	50.92




	Retention Time (min)	% Area
1	8.653	7.11
2	8.827	92.89









	Retention Time (min)	% Area
1	10.056	49.98
2	10.295	50.02





	Retention Time (min)	% Area
1	9.632	92.52
2	9.856	7.48






	Retention Time (min)	% Area
1	4.710	50.70
2	4.993	49.30




	Retention Time (min)	% Area
1	4.710	92.46
2	4.988	7.54









	Retention Time (min)	% Area
1	4.799	49.76
2	5.016	50.24





	Retention Time (min)	% Area
1	4.792	5.50
2	5.005	94.50







	Retention Time (min)	% Area
1	4.629	50.53
2	4.746	49.47







	Retention Time (min)	% Area
1	4.613	26.50
2	4.728	73.50
























	Retention Time (min)	% Area
1	3.783	44.61
2	4.111	55.39




	Retention Time (min)	% Area
1	3.779	77.99
2	4.105	22.01







	Retention Time (min)	% Area
1	4.663	49.66
2	5.036	50.34



	Retention Time (min)	% Area
1	4.654	89.82
2	5.018	10.18